The Patent Finder

Peptide Linkers for Polypeptide Compositions and Methods for Using Same

Shire LLC

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. 3 of these applications claim priority to application 61/449,225, filed Mar 4, 2011. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
PatentTitleHolderStatusExpiresTime remainingConfidence
US 8,580,922Peptide Linkers for Polypeptide Compositions and Methods for Using Same
In force
 · High confidence
Shire Human Genetic Therapies, Inc.In force
High confidence
US 11,065,307Therapeutic Fusion Protein Comprising an Alpha-N-Acetylglucosaminidase and a Lysosomal Targeting Moiety
In force
 · Low confidence
Takeda Pharmaceutical Company LimitedIn force
Low confidence
US 9,206,235Peptide Linkers for Polypeptide Compositions and Methods for Using Same
In force
 · Medium confidence
Shire Human Genetic Therapies, Inc.In force
Medium confidence
US 9,814,764Treatment of Sanfilippo Syndrome Type B by Intrathecal Administration of Alpha-N-Acetylglucosaminidase
In force
 · Medium confidence
Takeda Pharmaceutical Company LimitedIn force
Medium confidence
US 9,932,568Peptide Linkers for Polypeptide Compositions and Methods for Using Same
In force
 · High confidence
Shire Human Genetic Therapies, Inc.In force
High confidence
Application 13/168,969Treatment of Sanfilippo Syndrome Type B
Abandoned
Abandoned Jun 18, 2013
Shire Human Genetic Therapies, Inc.AbandonedAbandoned Jun 18, 2013
Application 17/350,909Treatment of Sanfilippo Syndrome Type B
Abandoned
Abandoned Feb 4, 2025
Takeda Pharmaceutical Company LimitedAbandonedAbandoned Feb 4, 2025
7 of 7 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
3 of these are in force and held by Shire LLC.
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited